The U.S. House of Representatives is preparing a suspension vote on the Lower Costs, More Transparency Act, which includes many of the controversial, overreaching proposals impacting pharmacy benefits. A recent Washington Examiner article highlighted growing concerns among Members of Congress
While debating important legislative proposals that can impact patients’ health and access to medications, the discussion should rely on solid facts and evidence. Today, we’re highlighting new reputable third-party research and analyses by economists which underscore that legislation focused on
Encouraging Signs that the Insulin Affordability Battle is Improving This week, as congressional hearings focus on access to affordable insulins, it should be recognized that a multitude of market forces are working to reduce the cost of insulin products for
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the final Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs rule: “PCMA applauds CMS for delaying the
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. THE GREAT DISPENSING DEBATE… Among ways that pharmacists are paid
Paying pharmacies more for dispensing medications will raise prescription drug costs without improving value.
In case you missed it, the growing consensus surrounding the recent actions from the Federal Trade Commission (FTC), including releasing an interim staff report on pharmacy benefit managers (PBMs) without substantial data to back up the wide sweeping claims and
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today announced that RxBenefits is joining the trade association as its newest member. “PCMA is proud to represent the pharmacy benefit industry, and the addition of RxBenefits to our membership once
The U.S. Senate Committee on the Judiciary held a hearing earlier this summer, “Ensuring Affordable & Accessible Medications: Examining Competition in the Prescription Drug Market.” Members of the Committee rightly diagnosed the root cause of out-of-control prescription drug prices in
Recently, several of the largest pharmaceutical manufacturers explained how pharmacy benefit managers (PBMs) are lowering prescription drug costs, specifically the highly priced GLP-1 weight loss drugs. Billions of dollars in direct-to-consumer and direct-to-physician advertising spending by drug companies have contributed
©2024 PCMA. All Rights Reserved.
